Dual-target antibody targeting VEGFR-2 and DLL4 and pharmaceutical composition including same
US10155817B2 · kind B2 · utility
0Cited by
0References
8Claims
0Family size
Assignee
Inventors
- Joong Kyu Kim
- Jin-San Yoo
- Sang Hoon Lee
- Weon Sup Lee
- Sung Woo Kim
- Sang Ryeol Shim
- Jin Sang Yoo
- Young Ae Lee
- Mi-ju PARK
- Sang Soon Byun
- Hyuk Joon Lee
- Do-yun Kim
- Yeun Ju Kim
- Jin Hee Choi
- Kyung Hee Nahm
- Ju Ryung Nam
- Jong Geun Jeong
- Bo Young Jeong
- Eun Jin Lee
- Seon Young Lee
- In Sook Park
- Jin Lee
- Jae Bong Yoon
- Nam Ye Kim
- Seon Hwan Oh
Key dates
| Filing date | Mar 14, 2018 |
| Grant date | Dec 18, 2018 |
| Priority date | — |
| Expiry date | Mar 14, 2038 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2333/705
- WIPO fieldMeasurement
- WIPO sectorInstruments
Abstract
The present invention relates to a novel form of a dual-target antibody targeting VEGFR-2 and DLL4, a gene encoding the same, a recombinant expression vector including the gene, host cells transformed with the recombinant expression vector, a method of producing the dual-target antibody using the host cells, a pharmaceutical composition comprising the dual-target antibody.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.